Can DCE-MRI reduce the number of PI-RADS v.2 false positive findings? Role of quantitative pharmacokinetic parameters in prostate lesions characterization.


Journal

European journal of radiology
ISSN: 1872-7727
Titre abrégé: Eur J Radiol
Pays: Ireland
ID NLM: 8106411

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 18 02 2019
revised: 16 06 2019
accepted: 01 07 2019
entrez: 24 8 2019
pubmed: 24 8 2019
medline: 31 12 2019
Statut: ppublish

Résumé

To test the potential impact of pharmacokinetic parameters, derived from DCE-MRI analysis, on the diagnostic performance of PI-RADSv.2 classification in prostate lesions characterization. Among patients who underwent multiparametric prostate MRI (mpMRI) (January 2016-March 2018) followed by histological evaluation (targeted biopsies/prostatectomy), 103 men were retrospectively selected. For each patient the index lesion was identified and pharmacokinetic parameters (Ktrans, Kep, Ve, Vp) were assessed. MRI diagnostic performance in the detection of significant tumors [Gleason Score (GS)≥7] was assessed, considering PI-RADS≥3 as positive. GS ≥ 7 (n = 59) showed higher Ktrans (p < 0.01) and Kep (p = 0.01) compared to GS < 7. At ROC curve analysis, a Ktrans cut-off of 191 × 10 Despite its high sensitivity prostate mpMRI generates many false positive cases: Ktrans in addition to PIRADS v.2 seems to improve MRI-PPV and may help in avoiding redundant biopsies.

Identifiants

pubmed: 31439258
pii: S0720-048X(19)30235-9
doi: 10.1016/j.ejrad.2019.07.002
pii:
doi:

Substances chimiques

Contrast Media 0

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

51-57

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Giulia Cristel (G)

Department of Radiology, Experimental Imaging Center, San Raffaele Scientific Institute, via Olgettina 60, 20132 Milan, Italy. Electronic address: cristel.giulia@hsr.it.

Antonio Esposito (A)

Department of Radiology, Experimental Imaging Center, San Raffaele Scientific Institute, via Olgettina 60, 20132 Milan, Italy; Vita Salute San Raffaele University, via Olgettina 60, 20132 Milan, Italy.

Anna Damascelli (A)

Department of Radiology, Experimental Imaging Center, San Raffaele Scientific Institute, via Olgettina 60, 20132 Milan, Italy.

Alberto Briganti (A)

Vita Salute San Raffaele University, via Olgettina 60, 20132 Milan, Italy; Department of Urology, San Raffaele Scientific Institute, via Olgettina 60, 20132 Milan, Italy.

Alessandro Ambrosi (A)

Vita Salute San Raffaele University, via Olgettina 60, 20132 Milan, Italy.

Giorgio Brembilla (G)

Department of Radiology, Experimental Imaging Center, San Raffaele Scientific Institute, via Olgettina 60, 20132 Milan, Italy; Vita Salute San Raffaele University, via Olgettina 60, 20132 Milan, Italy.

Lisa Brunetti (L)

Department of Radiology, Experimental Imaging Center, San Raffaele Scientific Institute, via Olgettina 60, 20132 Milan, Italy; Vita Salute San Raffaele University, via Olgettina 60, 20132 Milan, Italy.

Sofia Antunes (S)

Department of Radiology, Experimental Imaging Center, San Raffaele Scientific Institute, via Olgettina 60, 20132 Milan, Italy.

Massimo Freschi (M)

Department of Pathology, San Raffaele Scientific Institute, via Olgettina 60, 20132 Milan, Italy.

Francesco Montorsi (F)

Vita Salute San Raffaele University, via Olgettina 60, 20132 Milan, Italy; Department of Urology, San Raffaele Scientific Institute, via Olgettina 60, 20132 Milan, Italy.

Alessandro Del Maschio (A)

Department of Radiology, Experimental Imaging Center, San Raffaele Scientific Institute, via Olgettina 60, 20132 Milan, Italy; Vita Salute San Raffaele University, via Olgettina 60, 20132 Milan, Italy.

Francesco De Cobelli (F)

Department of Radiology, Experimental Imaging Center, San Raffaele Scientific Institute, via Olgettina 60, 20132 Milan, Italy; Vita Salute San Raffaele University, via Olgettina 60, 20132 Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH